BSX Stock Recent News
BSX LATEST HEADLINES
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Boston Scientific said on Friday the U.S. Food and Drug Administration has approved its device to treat a complication of heart disease.
Boston Scientific (BSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Boston Scientific BSX (NYSE: BSX) reported its Q4 results last month, with revenues and earnings comfortably beating the street estimates. The company reported revenue of $3.7 billion and adjusted earnings of $0.55 per share, compared to the consensus estimates of $3.6 billion and $0.51, respectively.
Boston Scientific (BSX) is benefitting from an impressive gain in MedSurg market share and the strong adoption of WATCHMAN FLX.
Boston Scientific (BSX) announces the completion of its first commercial cases with its FDA-cleared Farapulse PFA System in the United States.
Investors are optimistic about Boston Scientific (BSX) on strength across the target market and upbeat guidance.
Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?
Boston Scientific (BSX) secures FDA approval for the FARAPULSE PFA system.
Boston Scientific (BSX) sees an increase in organic and operational revenues in its core business segments and geographies in the reported quarter.